Citations Report
Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report
Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.
Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total published articles |
105 | 141 | 28 | 8 | 28 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
543 | 553 | 590 | 563 | 587 |
Journal total citations count | 6601 |
Journal impact factor | 6.49 |
Journal 5 years impact factor | 12.17 |
Journal cite score | 11.19 |
Journal h-index | 41 |
Journal h-index since 2019 | 26 |
Gurung, Jiwan, Dependra Chamlagai, Nirmal Kumar Bera, Tapas Kumar Chaudhuri, and Bisu Singh. "Elevated levels of C-reactive protein and IL-6 among the antipsychotic medicating schizophrenia patients of Siliguri, West Bengal, India." Nordic journal of psychiatry 72, no. 4 (2018): 311-317. |
|
Smyth, Annya M., and Stephen M. Lawrie. "The neuroimmunology of schizophrenia." Clinical psychopharmacology and neuroscience 11, no. 3 (2013): 107. |
|
Brissos, Sofia, Miguel Ruiz Veguilla, David Taylor, and Vicent Balanzá-Martinez. "The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal." Therapeutic advances in psychopharmacology 4, no. 5 (2014): 198-219. |
|
Cobo, Jesus, Javier Labad, Esther Pousa, Lourdes Nieto, Susana Ochoa, Judith Usall, Carles García-Ribera et al. "Exploring the relationship of insight with psychopathology and gender in individuals with schizophrenia spectrum disorders with structural equation modelling." Archives of women's mental health 23, no. 5 (2020): 643-655. |
|
Khandaker, Golam M. "Commentary: Causal associations between inflammation, cardiometabolic markers and schizophrenia: the known unknowns." International journal of epidemiology 48, no. 5 (2019): 1516-1518. |
|
Bartels, Stephen J., Karen L. Fortuna, and John A. Naslund. "Serious Mental Disorders in Older Adults: Schizophrenia and Other Late?Life Psychoses." Aging and Mental Health (2018): 241-280. |
|
Näätänen, Risto, Tetsuya Shiga, Satoko Asano, and Hirooki Yabe. "Mismatch negativity (MMN) deficiency: a break-through biomarker in predicting psychosis onset." International Journal of Psychophysiology 95, no. 3 (2015): 338-344. |
|
Balcioglu, Yasin Hasan, and Simge Seren Kirlioglu. "C-reactive protein/albumin and neutrophil/albumin ratios as novel inflammatory markers in patients with schizophrenia." Psychiatry Investigation 17, no. 9 (2020): 902. |
|
Gross, Gerhard, Karsten Wicke, and Karla U. Drescher. "Dopamine D 3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia." Naunyn-Schmiedeberg's archives of pharmacology 386, no. 2 (2013): 155-166. |
|
Gonzalez-Blanco, Leticia, Maria P. Garcia-Portilla, Leticia Garcia-Alvarez, Lorena de la Fuente-Tomas, Celso Iglesias Garcia, Pilar A. Saiz, and Julio Bobes. "Elevated C-reactive protein as a predictor of a random one-year clinical course in the first ten years of schizophrenia." Psychiatry research 269 (2018): 688-691. |
|
Agyapong, Vincent IO. "Factors predicting the presence of impaired clinical insight in liaison psychiatric patients assessed in the Emergency Room." International journal of psychiatry in clinical practice 20, no. 1 (2016): 32-39. |
|
Rapado-Castro, M., S. Dodd, A. I. Bush, G. S. Malhi, D. R. Skvarc, Z. X. On, M. Berk, and O. M. Dean. "Cognitive effects of adjunctive N-acetyl cysteine in psychosis." Psychological medicine 47, no. 5 (2017): 866-876. |
|
Kelly, Conor W., Joseph P. McEvoy, and Brian J. Miller. "Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study." Schizophrenia research 209 (2019): 193-197. |
|
Büchmann, Camilla Bakkalia, Geir Pedersen, Sofie Ragnhild Aminoff, Jannicke Fjæra Laskemoen, Elizabeth Ann Barrett, Ingrid Melle, and Trine Vik Lagerberg. "Validity of the Birchwood insight scale in patients with schizophrenia spectrum-and bipolar disorders." Psychiatry research 272 (2019): 715-722. |
|
Dantzer, Robert. "Psychiatric disorders and inflammation." Inflammation: From Molecular and Cellular Mechanisms to the Clinic (2017): 767-784. |
|
Citrome, Leslie. "Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains." The Journal of clinical psychiatry 75, no. suppl 1 (2014): 0-0. |
|
Arikan, Mehmet Kemal, Baris Metin, Sinem Zeynep Metin, Emine Elif Tülay, and Nevzat Tarhan. "High frequencies in QEEG are related to the level of insight in patients with schizophrenia." Clinical EEG and neuroscience 49, no. 5 (2018): 316-320. |
|
Schmidt, André, Rosilla Bachmann, Michael Kometer, Philipp A. Csomor, Klaas E. Stephan, Erich Seifritz, and Franz X. Vollenweider. "Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments." Neuropsychopharmacology 37, no. 4 (2012): 865-875. |
|
Rolin, Stephanie A., Kelly A. Aschbrenner, Karen L. Whiteman, Emily Scherer, and Stephen J. Bartels. "Characteristics and service use of older adults with schizoaffective disorder versus older adults with schizophrenia and bipolar disorder." The American Journal of Geriatric Psychiatry 25, no. 9 (2017): 941-950. |
|
Meltzer, Herbert Y., Lakshmi Rajagopal, Mei Huang, Yoshihiro Oyamada, Sunoh Kwon, and Masakuni Horiguchi. "Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia." International Journal of Neuropsychopharmacology 16, no. 10 (2013): 2181-2194. |
|